• Carbapenemase Gene Transmission in CREC Hospitals

  2026-09-10

  This 2025 BMC Microbiology study maps carbapenemase-encoding genes, their genomic location, transferability, and strain relatedness in carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. Its combination of plasmid analysis, conjugation testing, antimicrobial susceptibility profiling, and ERIC-PCR shows how blaNDM-1-associated resistance can spread through both mobile elements and related clinical lineages.

• EPZ5676: A Selective DOT1L Inhibitor Workflow

  2026-09-10

  EPZ5676 combines subnanomolar biochemical potency with strong selectivity, making it useful for connecting DOT1L target engagement to H3K79 methylation, gene expression, and leukemia-cell phenotypes. This workflow also adapts emerging multiple myeloma findings to test innate immune signaling and lenalidomide response in a controlled research setting.

• BMS-777607 for MET and Platelet Research

  2026-09-09

  BMS-777607 provides a practical ATP-competitive probe for MET-family signaling, from c-Met phosphorylation assays to cancer metastasis models. Its most disciplined cross-domain use is as an exploratory perturbation alongside, not instead of, validated hiPSC platelet-differentiation conditions.

• NETs in CML and Differential TKI Effects

  2026-09-09

  The reference study identifies increased neutrophil extracellular trap formation as a feature of chronic myeloid leukemia and shows that tyrosine kinase inhibitors do not affect this response uniformly. Its combination of patient-derived neutrophils, a BCR-ABL1-transduced differentiation model, and pathway-directed inhibitors provides a useful framework for investigating links between kinase therapy, inflammation, and vascular toxicity.

• Otilonium Bromide: From Target to Assay Design

  2026-09-08

  Otilonium Bromide is an antimuscarinic agent for dissecting cholinergic signaling in neuronal and smooth-muscle models. This article connects receptor pharmacology, assay architecture, product handling, and lessons from structure-based inhibitor screening without overstating translational evidence.

• Fluorescein TSA Kit for Astrocyte Mapping

  2026-09-08

  Discover how the Fluorescein TSA Fluorescence System Kit can translate astrocyte atlas findings into sensitive spatial validation. This article connects regional and developmental heterogeneity with assay design, controls, and interpretation for IHC, ICC, and ISH.

• Bromodomain Inhibitor, (+)-JQ1: Applied Workflows

  2026-09-07

  Learn how to deploy (+)-JQ1 in adipogenesis, apoptosis, inflammation, and BRDT-focused research workflows. The guide combines mechanistic interpretation with practical dosing, controls, storage guidance, and troubleshooting for reproducible BET inhibition.

• Novobiocin in Reliable Viability Assays

  2026-09-07

  Learn how Novobiocin (SKU BA1116) can be integrated into antimicrobial, antiparasitic, antiviral, and cell-based viability workflows without confusing pathogen suppression with host-cell toxicity. This scenario-driven guide covers concentration selection, solvent controls, assay compatibility, interpretation, storage, and practical vendor evaluation.

• SU5416: A Metabolic Lens on Angiogenesis

  2026-09-05

  SU5416 (Semaxanib) is more than a VEGFR2 inhibitor: it can serve as a mechanistic probe for separating receptor-driven angiogenesis from metabolically activated HIF1α signaling. This article translates recent vascular-metabolism findings into sharper assay design and interpretation.

• IDH1-R132H Autopalmitoylation in Cancer Metabolism

  2026-09-04

  The reference study identifies C269 autopalmitoylation as a mutation-conferred regulatory modification that strengthens IDH1-R132H substrate and cofactor binding, dimerization, and production of the oncometabolite 2-HG. By connecting fatty-acid availability to mutant IDH1 activity, the work defines a mechanistically testable and potentially druggable vulnerability in IDH1-mutant cancers.

• KX2-391 Dihydrochloride: Assay Logic

  2026-09-04

  KX2-391 dihydrochloride is a mechanistically rich probe for Src signaling, tubulin dynamics, HBV transcription, and BoNT/A activity. This evidence-led guide shows how to choose endpoints, interpret concentration ranges, and avoid conflating biochemical potency with cellular or translational effects.

• miR-24-3p/Sp1/PI3K in Doxorubicin HF

  2026-09-03

  This study identifies miR-24-3p as a direct suppressor of Sp1 and links its activity to PI3K signaling in doxorubicin-induced heart failure. By combining rat and cardiomyocyte models with gain- and loss-of-function experiments, the work suggests that miR-24-3p silencing can reduce apoptosis and oxidative stress, although clinical translation remains unestablished.

• LY2603618: Chk1 Inhibitor Workflow Guide

  2026-09-03

  LY2603618 provides a focused way to interrogate Chk1-dependent checkpoint control, DNA damage accumulation, and chemotherapy sensitization in cancer models. This guide translates its reported cell-based conditions into practical workflows while clarifying how the compound can—and cannot—be used to study the nuclear cGAS–TRIM41 pathway described in recent genome-integrity research.

• Pazopanib Hydrochloride: Assay-Ready Insight

  2026-09-02

  Pazopanib Hydrochloride is a multi-target kinase inhibitor whose apparent activity can reflect both growth arrest and cell killing. This article translates Schwartz’s assay research into a practical framework for interpreting GW786034 responses in cancer research and anti-angiogenic studies.

• Capsazepine Workflows for TRPV1 Pain Research

  2026-09-02

  Use Capsazepine as a receptor-level pharmacology tool to separate TRPV1-dependent nociception from broader inflammatory and affective pain mechanisms. This workflow combines calcium imaging, sensory assays, TRPM8 counter-screening, and apoptosis studies while emphasizing solvent control and off-target troubleshooting.

8008 records 1/534 page Next 12345 下5页 Last page